Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
Status:
Completed
Trial end date:
2006-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is
effective in the treatment of dyskinesia associated with dopaminergic treatment of
Parkinson's disease (PD).